Acino Pharma GmbH
Acino Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe, the Middle East, and Africa. Founded in 1836, Acino has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals, focusing on areas such as pain management, cardiovascular health, and central nervous system disorders. The company is renowned for its innovative drug delivery systems and patient-centric solutions, which set its products apart in a competitive market. With a commitment to quality and sustainability, Acino has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. As a trusted name in healthcare, Acino Pharma continues to make strides in improving patient outcomes through its diverse portfolio of effective medications.
DitchCarbon Score
How does Acino Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acino Pharma GmbH's score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acino Pharma GmbH's reported carbon emissions
Acino Pharma GmbH, headquartered in Germany, currently does not have publicly available carbon emissions data or specific reduction targets. The absence of emissions figures suggests that the company may still be in the early stages of formalising its climate commitments. In the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to adopt science-based targets to reduce their carbon footprint. While Acino Pharma has not disclosed specific initiatives or commitments, the industry trend indicates a growing focus on reducing Scope 1, 2, and 3 emissions. As the company progresses, it may align with broader climate goals and industry standards to enhance its environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acino Pharma GmbH is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
